FDA approves Shire's constipation drug

FDA approved Motegrity prucalopride from Shire plc (LSE:SHP; NASDAQ:SHPG) to treat chronic idiopathic constipation (CIC) in adults. The approval came a week ahead of the drug's Dec. 21 PDUFA date.

Shire markets prucalopride, an agonist of serotonin (5-HT4) receptor, in the EU as Resolor. The company obtained the drug’s U.S. rights from Johnson & Johnson (NYSE:JNJ) in 2012...